HIV
Cambodia may struggle to meet its goal of reducing new HIV infections to less than one person per day by 2030, with the current rate sitting at over three people per day. The National AIDS Authority (NAA) has set a target to decrease the number of new HIV infections from
HIV
Researchers at the 25th International AIDS Conference in Munich, Germany, announced a significant breakthrough in HIV prevention using the novel twice-yearly injectable lenacapavir. The emerging data from the PURPOSE 1 trial demonstrated 100% efficacy in preventing HIV infection in cisgender women. The President of the International AIDS Society, Sharon Lewin,
Clinical trials
The international AIDS conference, held in Munich, Germany, from 22 to 26 July 2024, announced the results of the PURPOSE 1 trial, showcasing the 100% efficacy of lenacapavir in preventing HIV in cisgender women. These findings have significant implications for the global fight against HIV, particularly in high-risk populations. The
